Active · per the CBE, 16 November 2026

REJUVENATE BIOMED

BE0681964735

Rechtspersoon Public limited company 1 establishment

REJUVENATE BIOMED is a research organisation in Diepenbeek. Public Limited, started on 2 October 2017, 1 establishment.

Agoralaan A-bis, 3590 Diepenbeek

Active for

9 year, 1 month

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

  • Negative equity NBB

    More debt than assets in 2 of the last 4 fiscal years.

  • Two loss years in a row NBB

    Negative result in 2024 and 2025.

Financials

Financial year 2025

REJUVENATE BIOMED from Diepenbeek, company number BE0681964735, closed financial year 2025 with a result of € -3.3 million after tax. For that financial year REJUVENATE BIOMED recorded a gross margin of € 3.1 million and equity of € -543,937. Compared with financial year 2024, the result moved from € -3.2 million to € -3.3 million. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 30, 2026.

What it is worth Caution

€ -543,937

▲ € 582,684 vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -3.3 million

▼ 2 % more loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 2.2 million

▼ 25% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -21.1 million.

People and assets in 2025

Full-time equivalents

11

▲ 2.4 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 1.8 million

▲ 38% vs 2024

€ 163,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 198,260

▼ 5% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

€ 2.2 million

▼ 29% vs 2024

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 235,271

▼ 52% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 180,320

▲ 19% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year
2022202320242025Change 2024 → 2025
Gross margin € 898,372 € 379,830 € 1,174,815 € 3,091,749 ▲ 163%
Profit after taxes € -4,474,472 € -5,066,530 € -3,231,114 € -3,284,037 ▼ € 52,924
Equity € 6,323,023 € 2,104,493 € -1,126,621 € -543,937 ▲ € 582,684
Total debts € 773,292 € 874,939 € 5,376,649 € 3,997,115 ▼ 26%
Cash € 6,077,105 € 2,034,638 € 2,965,168 € 2,223,566 ▼ 25%
Retained profit € -9,563,822 € -14,630,352 € -17,861,466 € -21,145,503 ▼ € 3.3 million
Bank debt € 0 € 452,667 € 3,137,388 € 2,213,441 ▼ 29%
Balance sheet total € 7,096,315 € 2,979,432 € 4,250,029 € 3,453,178 ▼ 19%
Employees (FTE) 5.9 7.6 8.6 11 ▲ 2.4

Key figures of REJUVENATE BIOMED, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to REJUVENATE BIOMED?

What happened at REJUVENATE BIOMED in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

  • Ann Beliën stepped down as director. NBB
  • Stéphane Verdood stepped down as director. NBB
  • Glenn Van Dael stepped down as director. NBB
  • Sunathim BV stepped down as director. NBB
  • Capital increase published in the Gazette. Source: Staatsblad ↗
  • New annual accounts for financial year 2025: loss of € 3.3 million. Source: NBB ↗
  • Capital increase of € 3.9 million, published in the Gazette. Source: Staatsblad ↗
  • Capital increase of € 848,000, published in the Gazette. Source: Staatsblad ↗

In short

From € 4.5 million loss in 2022 to € 3.3 million loss in 2025.

On average € 281,100 of value added per employee in 2025.

Management

C-THAT 0.8%

The stake of C-THAT comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

REJUVENATE BIOMED

The shares are held by C-THAT (0.8%).

Directors

According to the 2025 annual accounts

Sunathim BV

Director · represented by Shetty Sunangal Ajit

Also active at: SOUDAL HOLDING, reMYND, Newton Biocapital I, pricaf privée de droit belge, Newton Biocapital II

since 2022 · until 2028

Ann Beliën

Managing director

since 2017 · until 2029

Stéphane Verdood

Director

since 2021 · until 2029

Glenn Van Dael

Director

since 2017 · until 2029

Shareholders

C-THAT

0.8%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Agoralaan A-bis

3590 Diepenbeek

2.335.620.636

Agoralaan 1 box A

3590 Diepenbeek

Active since 1 July 2022

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 4 companies are registered at this address.

All companies at this address →

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Shareholders according to the Official Gazette deeds

Who contributed at incorporation and at capital increases, with the deed as source. Later share transfers are not published in the Gazette.

Capital increase

Source: Deed ↗
  • VESALIUS BIOCAPITAL III S.C.A. SICAR(inschrijver converteerbare lening (conversie in Bevoorrechte Klasse C1 Aandelen)) 9.7%
  • LIMBURGSE RECONVERSIE MAATSCHAPPIJ(inschrijver converteerbare leningen (conversie in Bevoorrechte Klasse C2 Aandelen)) 1.6%
  • PROGR3SS(inschrijver converteerbare lening (conversie in Bevoorrechte Klasse C1 Aandelen)) 1%
  • DESMEDT Koen en FRANSSEN Linda(inschrijver converteerbare lening (conversie in Bevoorrechte Klasse C1 Aandelen)) 0.5%
  • BRAMS Hilde(inschrijver converteerbare lening (conversie in Bevoorrechte Klasse C1 Aandelen)) 0.4%
  • SUY Peter(inschrijver converteerbare lening (conversie in Bevoorrechte Klasse C1 Aandelen)) 0.3%
  • DECORTE Michel(inschrijver converteerbare lening (conversie in Bevoorrechte Klasse C1 Aandelen)) 0.3%
  • SLAUS Gunther(inschrijver converteerbare lening (conversie in Bevoorrechte Klasse C1 Aandelen)) 0.3%
  • VOS Bart(inschrijver converteerbare lening (conversie in Bevoorrechte Klasse C1 Aandelen)) 0.3%
  • BELIËN Ann(inschrijver converteerbare lening (conversie in Bevoorrechte Klasse C1 Aandelen)) 0.3%
  • DYFAN INVESTMENT(inschrijver converteerbare lening (conversie in Bevoorrechte Klasse C1 Aandelen)) 0.2%
  • PEREZ CARMONA Antonio(inschrijver converteerbare lening (conversie in Bevoorrechte Klasse C1 Aandelen)) 0.2%
  • MATHÉ Frans(inschrijver converteerbare lening (conversie in Bevoorrechte Klasse C1 Aandelen)) 0.2%
  • MOSTMANS Jef(inschrijver converteerbare lening (conversie in Bevoorrechte Klasse C1 Aandelen)) 0.2%
  • DE SCHEPPER Jochen(inschrijver converteerbare lening (conversie in Bevoorrechte Klasse C1 Aandelen)) 0.2%
  • DYSELINCK Kris(inschrijver converteerbare lening (conversie in Bevoorrechte Klasse C1 Aandelen)) 0.2%
  • MATHE Frans(inschrijver nieuwe Bevoorrechte Klasse C1 Aandelen (inbreng in geld, 23,16 EUR per aandeel)) 0.2%
  • BEERNAERT Koen(inschrijver converteerbare lening (conversie in Bevoorrechte Klasse C1 Aandelen)) 0.2%
  • ADRIAENSSENS Geert(inschrijver converteerbare lening (conversie in Bevoorrechte Klasse C1 Aandelen)) 0.2%
  • KRILL Patricia(inschrijver converteerbare lening (conversie in Bevoorrechte Klasse C1 Aandelen)) 0.2%
  • STEEGMANS Gert en MENSCH Iris(inschrijver converteerbare lening (conversie in Bevoorrechte Klasse C1 Aandelen)) 0.1%
  • VAN DESSEL Filip(inschrijver converteerbare lening (conversie in Bevoorrechte Klasse C1 Aandelen)) 0.1%
  • CLAASSEN Richard(inschrijver nieuwe Bevoorrechte Klasse C1 Aandelen (inbreng in geld, 23,16 EUR per aandeel)) 0.1%
  • JACOBS Daniel(inschrijver converteerbare lening (conversie in Bevoorrechte Klasse C1 Aandelen)) 0.1%
  • VOS Filip(inschrijver converteerbare lening (conversie in Bevoorrechte Klasse C1 Aandelen)) 0.1%
  • NEVEN Lizzy Anne(inschrijver converteerbare lening (conversie in Bevoorrechte Klasse C1 Aandelen)) 0.1%
  • PMD CONSULTING(inschrijver nieuwe Bevoorrechte Klasse C1 Aandelen (inbreng in geld, 23,16 EUR per aandeel)) 0%
  • PMD CONSULTING HOLDING(inschrijver converteerbare lening (conversie in Bevoorrechte Klasse C1 Aandelen)) 0%

Capital increase

Source: Deed ↗
  • VESALIUS BIOCAPITAL III S.C.A. SICAR(inschrijver) 5.3%
  • LIMBURGSE RECONVERSIE MAATSCHAPPIJ(inschrijver) 1.1%
  • BACKAERT Jan Simon Jozef Maria(inschrijver) 1%
  • CLAASSEN Richard Joseph Hyacinthus Stanislaus(inschrijver) 0.9%
  • BRAECKMAN Kurt Armand M(inschrijver) 0.9%
  • PROGR3SS(inschrijver) 0.7%
  • VAN DESSEL Filip René J(inschrijver) 0.5%
  • BEERNAERT Koen André C(inschrijver) 0.5%
  • SLAUS Gunter Pieter(inschrijver) 0.4%
  • VOS Bart(inschrijver) 0.4%
  • DYSELINCK Kris Gerard A(inschrijver) 0.4%
  • MOSTMANS Jozef Maria(inschrijver) 0.4%
  • DE SCHEPPER Jochen(inschrijver) 0.4%
  • WOUTERS Jan Frans J(inschrijver) 0.4%
  • BRAMS Hilde(inschrijver) 0.4%
  • STEEGMANS Gert Jo M(inschrijver) 0.4%
  • PEREZ CARMONA Antonio Francisco(inschrijver) 0.4%
  • TWO INVEST(inschrijver) 0.2%
  • VOS Filip Edmond L(inschrijver) 0.2%
  • JACOBS Daniel Frans M(inschrijver) 0.2%

Capital increase

Source: Deed ↗
  • VESALIUS BIOCAPITAL III S.C. A.(inschrijver) 2.6%
  • LIMBURGSE RECONVERSIE MAATSCHAPPIJ, afgekort L R M(inschrijver) 1.4%

Incorporation

Source: Deed ↗
  • BELIËN Ann Trudo Josee(oprichter) 95%
  • C-THAT(oprichter) 5%

Details

Company number
0681.964.735
VAT number
BE 0681.964.735
Registered office
Agoralaan A-bis, 3590 Diepenbeek
Names & denominations
REJUVENATE BIOMED
Enterprise type
Rechtspersoon
Legal form
Public limited company
Legal situation
Normale toestand
Start date
2 October 2017
Peppol
Active · Active since 30 Oct 2025
Activities · NACE

Speur- en ontwikkelingswerk op biotechnologisch gebied

Vervaardiging van farmaceutische grondstoffen

Frequently asked questions

What does REJUVENATE BIOMED do?
REJUVENATE BIOMED is a research organisation in Diepenbeek. Public Limited, started on 2 October 2017, 1 establishment.
What is the address of REJUVENATE BIOMED?
The registered office of REJUVENATE BIOMED is located at Agoralaan A-bis, 3590 Diepenbeek.
Is REJUVENATE BIOMED still active?
Yes. According to the CBE (16 November 2026) REJUVENATE BIOMED is active, legal situation “Normale toestand”, started on 2 October 2017.
Is REJUVENATE BIOMED registered on Peppol?
Yes, REJUVENATE BIOMED is registered on the Peppol network with ID 0208:0681964735.
What is the enterprise number of REJUVENATE BIOMED?
The enterprise number of REJUVENATE BIOMED is BE0681964735.
When was REJUVENATE BIOMED founded?
REJUVENATE BIOMED was founded on 2 October 2017.